Pharmaceuticals January 27, 2025
Abelacimab Stops Bleeding, But Stroke Impact Uncertain January 27, 2025
Fully published results from Athos Therapeutics’ AZALEA-TIMI 71 trial for its novel Factor XI inhibitor abelacimab confidently reasserted the drug’s stunning lower bleeding risks but left researchers uncertain about its ability to prevent stroke in AFib patients.
Obesity Care January 23, 2025
The Potential Risks of GLP-1s January 23, 2025
Although GLP-1s have proven to significantly help with weight loss and cardiometabolic disorders, a new Nature Medicine study shed light on the drugs’ potential side-effects.
Heart Failure January 16, 2025
The Finer Points of FINEARTS-HF January 16, 2025
Bayer’s FINEARTS-HF study revealed that finerenone could be poised to become the next big heart failure treatment at ESC 2024, and a new series of JACC sub-studies have further strengthened its case.
Cardiac Imaging January 13, 2025
AI-CCTA Beats SPECT, Again January 13, 2025
Top Story Meta Description: A recent study out of UCLA added to the growing body of evidence supporting AI-assisted CCTA as an alternative to SPECT for diagnosing obstructive coronary artery disease, especially in women.
Artificial Intelligence January 9, 2025
AI-ECG’s 2025 Kickoff January 9, 2025
The buzz around artificial intelligence’s impact on cardiology keeps growing louder, and that’s proving to be particularly true in the AI-ECG segment, with 2025 already off to a strong start from ECG startups and researchers alike.
Controversies January 6, 2025
Cardiologists Busted for Overbilling Nationwide January 6, 2025
16 cardiology practices across 12 states agreed to pay more than $17.7M to resolve allegations that they overbilled for diagnostic radiopharmaceuticals and violated the False Claims Act.
Controversies December 19, 2024
Challenging the CHAGASICS Trial December 19, 2024
Exposing the failures of peer review, Dr. Anis Rassi Jr. MD, PhD, recently published his letter to JAMA Cardiology in Sensible Medicine about glaring issues with the CHAGASICS trial.
Structural Heart December 16, 2024
Capstan’s Robotic MR/TR Frontier Funding December 16, 2024
Capstan Medical took a key step towards its vision of launching the first robotic cardiac valve surgery system, landing $110M in Series C funding.
Cholesterol Reduction December 12, 2024
NewAmsterdam’s BROADWAY Show December 12, 2024
Topline results from NewAmsterdam’s Phase 3 BROADWAY trial provided the strongest evidence yet of obicetrapib’s potential for patients with ASCVD and heterozygous familial hypercholesterolemia who can’t lower their LDL-C with statins.
Pharmaceuticals December 9, 2024
Tirzepatide Triumphant Over Semaglutide December 9, 2024
Topline results from the SURMOUNT-5 trial found Eli Lilly’s tirzepatide led to far greater weight loss than Novo Nordisk’s semaglutide, giving Lilly a boost in the race to become America’s go-to GLP-1.
Pharmaceuticals December 5, 2024
MariTide’s Weight Loss Milestone December 5, 2024
The red hot weight loss segment just got even hotter, as the Phase 2 trial of Amgen’s maridebart cafraglutide (MariTide) yielded exceptional body mass reductions among people with obesity and T2D, propelling the pharma giant closer to FDA approval.
Pharmaceuticals December 2, 2024
Winrevair’s Big PAH Win December 2, 2024
Stunning topline results from Merck Winrevair’s Phase 3 ZENITH trial found that the drug significantly reduced morbidity and mortality risks in patients with pulmonary arterial hypertension, paving the way for stronger commercialization and further functional trials.
Cholesterol Reduction November 25, 2024
Muvalaplin Aces Phase 2 Lp(a) Test November 25, 2024
Impressive results from the Phase 2 KRAKEN trial presented at the AHA 2024 Scientific Sessions showed that Eli Lilly’s muvalaplin greatly reduces Lp(a) blood levels, adding an attractive oral option to its Lp(a) pipeline.
Cardiology November 21, 2024
Ablation or Antiarrhythmics for Ventricular Tachycardia? November 21, 2024
Late-breaking results from the VANISH2 trial presented at AHA 2024 showed that catheter ablation might be a better first-line treatment than antiarrhythmic drugs for ventricular tachycardia patients with ischemic cardiomyopathy.
Pharmaceuticals November 18, 2024
Tirzepatide’s Prediabetes Triumph November 18, 2024
Eli Lilly’s GLP-1 tirzepatide has triumphed yet again, as the full SURMOUNT-1 trial showed that the drug kept nearly 99% of prediabetic patients diabetes-free over 3 years, while improving cardiometabolic metrics.
Surgeries & Interventions November 14, 2024
Forgotten IVC Filters Aren’t SAFE November 14, 2024
Troubling results from the SAFE-IVC study revealed that just one in six patients gets their inferior vena cava filters removed, despite clear guidelines calling for IVC filter removal as early as possible.
Surgeries & Interventions November 11, 2024
LimFlow Limits Limb-Threatening Ischemia November 11, 2024
Late-breaking second year results from the PROMISE II trial showed that the LimFlow system achieved strong outcomes for avoiding amputations and promoting limb salvage among “no-option” patients with chronic limb-threatening ischemia.
Atrial Fibrillation November 7, 2024
Boston Scientific Bolsters AFib Mapping with Cortex Acquisition November 7, 2024
Boston Scientific made what could become a major addition to its electrophysiology portfolio, acquiring AFib mapping startup Cortex, Inc. for an undisclosed sum.
Surgeries & Interventions November 4, 2024
TCT 2024’s Top TAVR Studies November 4, 2024
This year’s TCT conference saw a deluge of TAVR trials examining everything from the efficacy of valve designs to TAVR’s impact on aortic and tricuspid regurgitation. Out of all these TAVR studies, the four that could have the greatest clinical impact focused on interventional timing and the risk of comorbidities and procedural complications.